Houston pharma co. lands nearly $11M investment from Chicago group
A Houston-based pharmaceutical company targeting epigenetic — or, non-genetic — causes of cancer has new capital to develop its cancer drug.
Houston-based Salarius Pharmaceuticals Inc. (Nasdaq: SLRX) entered into a $10.9 million common stock purchase agreement with Chicago-based institutional investor Aspire Capital Fund LLC, according to an Oct. 28 pre ss release. The agreement allows for Aspire Capital to purchase up to $10.9 million in common stock over a 30-month period through 2022, per…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Chris Mathews Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Genetics | Health Management | Pharmaceuticals